Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JW PharmaceuticalXKRX:001060 +1.23%90 Pretax Margin % is 17.61% as of Mar. 2026, which is 565% above its 10-year median of 2.65. GuruFocus rates XKRX:001060 with a GF Score™ of 90/100 and a GF Value™ of ₩32,148.31 (Modestly Undervalued). Among 958 Drug Manufacturers companies, JW Pharmaceutical ranks better than 64.41% on this metric.
The historical rank and industry rank for JW Pharmaceutical's Pretax Margin % or its related term are showing as below:
XKRX:001060'
s Pretax Margin % Range Over the Past 10 Years
Min: -6.71 Med: 2.65 Max: 12.81
Current: 12.81
XKRX:001060's Pretax Margin % is ranked better than 64.41% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7
vs XKRX:001060: 12.81
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
JW Pharmaceutical Pretax Margin % Related Terms
JW Pharmaceutical Pretax Margin % Historical Data
* Premium members only.
The historical data trend for JW Pharmaceutical's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JW Pharmaceutical's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW Pharmaceutical Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JW Pharmaceutical's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where JW Pharmaceutical's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW Pharmaceutical (XKRX:001060) has a Pretax Margin % of 17.61% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on JW Pharmaceutical and its competitors. This is 565% above median its historical median of 2.65. According to the industry distribution chart, JW Pharmaceutical ranks #341 out of 958 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is JW Pharmaceutical's Pretax Margin % too high?
JW Pharmaceutical's current Pretax Margin % of 17.61% is 565% above median its 10-year median of 2.65. The Drug Manufacturers industry median Pretax Margin % is 7.00. JW Pharmaceutical's value of 17.61% is 151.6% above this industry median. Based on the distribution chart, JW Pharmaceutical ranks #341 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, JW Pharmaceutical has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JW Pharmaceutical's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JW Pharmaceutical ranks #341 out of 958 companies for Pretax Margin %. This puts JW Pharmaceutical in the upper half of its industry. The industry median Pretax Margin % is 7.00. JW Pharmaceutical's value of 17.61% is 151.6% above this benchmark. While the company's 10-year median is 2.65 vs. the industry median of 7.00, JW Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW Pharmaceutical's current Pretax Margin % of 17.61% is 151.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on JW Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW Pharmaceutical's current Pretax Margin % is 17.61%, which is 565% above median its own 10-year median of 2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, JW Pharmaceutical (XKRX:001060) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩32,148.31, compared to a current price of ₩28,850.00 — trading 10.3% below its estimated fair value. The current Pretax Margin % is 17.61%, which is 565% above median its 10-year median of 2.65 and 151.6% above the Drug Manufacturers industry median of 7.00. JW Pharmaceutical's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For JW Pharmaceutical (XKRX:001060), the current Pretax Margin % is 17.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW Pharmaceutical (XKRX:001060) Overvalued in 2026?
Based on GuruFocus' analysis, JW Pharmaceutical stock appears to be undervalued.
The current stock price of ₩28,850.00 is trading 10.3% below its estimated GF Value™ of ₩32,148.31.
GuruFocus considers JW Pharmaceutical to be Modestly Undervalued.
Key valuation signals for XKRX:001060:
Pretax Margin %: 17.61% (565% above median its 10-year median of 2.65)
GF Value™: ₩32,148.31 vs. price of ₩28,850.00 (10.3% below fair value)
Industry Position: 151.6% above the Drug Manufacturers median (#341 of 958)
No single metric tells the full story. See the XKRX:001060 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
90GF Score
Get the complete analysis for XKRX:001060
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:001060 has been successfully added to your 
